<DOC>
	<DOCNO>NCT00299819</DOCNO>
	<brief_summary>The primary objective study evaluate safety tolerability intravenously administer MEDI-545 compare placebo , dose escalation range 0.3-30 mg/kg , adult patient SLE receive 20 mg/day less prednisone orally equivalent dose another oral corticosteroid .</brief_summary>
	<brief_title>Safety Tolerability MEDI-545 Patients Who Have Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>The primary objective study evaluate safety tolerability intravenously administer MEDI-545 compare placebo , dose escalation range 0.3-30 mg/kg , adult patient SLE receive 20 mg/day less prednisone orally equivalent dose another oral corticosteroid . The secondary objective study describe pharmacokinetics potential immunogenicity MEDI-545 .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Patients must meet following criterion : Adult male female ≥ 18 year time first dose study drug . Written inform consent obtain patient/patient 's legal guardian Diagnosis SLE : Patients must previously meet ≥ 4 11 revise ACR criterion Current background treatment may include follow medication prior randomization : acetaminophen , nonsteroidal antiinflammatory drug ( NSAIDs ) , antimalarial , hydroxychloroquine ≤ 600 mg/day , prednisone ≤ 20 mg daily ( equivalent dose another oral corticosteroid ) least 28 day Sexually active female , unless surgically sterile least two year postmenopausal , must use effective method avoid pregnancy ( include oral , injectable , transdermal , implanted contraceptive , IUD , female condom , diaphragm spermicide , cervical cap , abstinence , use condom sexual partner sterile sexual partner ) 28 day first dose study drug , must agree continue use precaution study period 84 day . Cessation birth control point discuss responsible physician . Sexually active male , unless surgically sterile , must likewise use effective method birth control ( condom abstinence ) must agree continue use precaution Study Day 84 . Ability complete followup period 84 day require protocol . Weight ≥ 120 kg Use cyclophosphamide , azathioprine , methotrexate , mycophenolate mofetil cyclosporine within 28 day study entry Use dose corticosteroid higher equivalent prednisone 20 mg/day ( equivalent dose another corticosteroid ) within 28 day study entry In opinion investigator , likelihood require initiation immunosuppressant therapy ( e.g. , prednisone &gt; 20 mg daily ( equivalent dose another oral corticosteroid ) , azathioprine , mycophenolate mofetil , cyclosporine , methotrexate , dapsone ) within 28 day study entry . Antimalarial dosing must hold constant study , analgesic NSAIDs may vary . Current treatment coumadin Treatment immunoglobulin blood product within 28 day entry study Treatment investigational drug therapy within 28 day entry study ; case celldepleting therapy , B T cell depletion , cell count remain acceptable baseline level ( use license agent indication list package insert permit ) History primary immunodeficiency History allergic reaction likely exacerbate component study drug Previous medical history , evidence , intercurrent illness , SLE , may compromise safety patient study Clinically significant cardiac disease , include : unstable angina ; myocardial infarction within 6 month ; congestive heart failure ; arrhythmia require active therapy , exception clinically insignificant extra systole , minor conduction abnormality ; history clinically significant abnormality electrocardiogram Evidence significant active infection , vaccination live attenuate virus , currently 2 week randomization Evidence infection hepatitis B C virus , HIV1 HIV2 , active infection hepatitis A , determined result test screen A history severe infection virus herpes family include EpsteinBarr virus require hospitalization , disseminate herpes , herpes encephalitis , ophthalmic herpes , cytomegalovirus Herpes zoster ≤ 3 month prior screen Current suppressive antiviral therapy herpes viral infection Ongoing , chronic infectious disease chronic renal infection chronic chest infection bronchiectasis sinusitis Pregnancy ( female , unless surgically sterile least two year postmenopausal must negative serum pregnancy test within 14 day receive study drug negative urine pregnancy test Study Day 0 receive study drug ) Nursing mother History alcohol drug abuse within past 2 year Presence endstage renal disease , rapidly progressive glomerulonephritis Active central nervous system lupus History stroke , cerebrovascular disease require medication/treatment . History cancer , apart basal cell carcinoma situ carcinoma cervix treat apparent success curative therapy &gt; 1 year prior enrollment At screen ( must within14 day entry study ) following : AST &gt; 1.5x upper limit normal range ( ULN ) ALT &gt; 1.5x ULN creatinine &gt; 1.5x ULN patient 's age , sex weight serum K normal range hemoglobin &lt; 8 g/dL white blood cell count &lt; 1,800/mm3 ( Superscript ) neutrophils &lt; 1,500/mm3 ( Superscript ) platelet count &lt; 50,000/mm3 ( Superscript ) abnormal laboratory value screen panel opinion principal investigator judge potentially confound analysis study result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Lupus</keyword>
</DOC>